StockData
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. (AUPH) stock

AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3058% below fair value
$15.13−0.27 (-1.75%)

Close on Nov 18, 2026Market cap $2.03BP/E 6.6Yield –

Aurinia Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Aurinia Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was $156.37M, up 123.4% year over year. For fiscal 2025 it was $104.91M. The highest annual figure on record is $104.91M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$104.91M–
FY2024Dec 31, 2024-$4.69M–
FY2023Dec 31, 2023-$91.69M–
FY2022Dec 31, 2022-$111.47M–
FY2021Dec 31, 2021-$180.74M–
FY2020Dec 31, 2020-$104.29M–
FY2019Dec 31, 2019-$90.94M–
FY2018Dec 31, 2018-$55.24M–
FY2017Dec 31, 2017-$46.87M–
FY2016Dec 31, 2016-$25.03M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$35.36M+18.9%
Q2 FY2026Jun 30, 2026$46.34M+130.7%
Q1 FY2026Mar 31, 2026$41.42M+89.6%
Q4 FY2025Dec 31, 2025$33.24M–
Q3 FY2025Sep 30, 2025$29.75M+153.2%
Q2 FY2025Jun 30, 2025$20.08M–
Q1 FY2025Mar 31, 2025$21.85M–
Q4 FY2024Dec 31, 2024-$1.67M–
Q3 FY2024Sep 30, 2024$11.75M–
Q2 FY2024Jun 30, 2024-$1.51M–
Q1 FY2024Mar 31, 2024-$13.25M–
Q4 FY2023Dec 31, 2023-$29.67M–
Q3 FY2023Sep 30, 2023-$16.26M–
Q2 FY2023Jun 30, 2023-$16.17M–
Q1 FY2023Mar 31, 2023-$29.58M–
Q4 FY2022Dec 31, 2022-$28.10M–
Q3 FY2022Sep 30, 2022-$9.50M–
Q2 FY2022Jun 30, 2022-$35.99M–
Q1 FY2022Mar 31, 2022-$37.88M–
Q4 FY2021Dec 31, 2021-$32.71M–
Q3 FY2021Sep 30, 2021-$50.35M–
Q2 FY2021Jun 30, 2021-$47.13M–
Q1 FY2021Mar 31, 2021-$50.54M–
Q4 FY2020Dec 31, 2020-$8.05M–
Q3 FY2020Sep 30, 2020-$42.32M–
Q2 FY2020Jun 30, 2020-$26.86M–
Q1 FY2020Mar 31, 2020-$27.06M–
Q4 FY2019Dec 31, 2019-$34.84M–
Q3 FY2019Sep 30, 2019-$24.07M–
Q2 FY2019Jun 30, 2019-$17.14M–
Q1 FY2019Mar 31, 2019-$14.89M–

More Aurinia Pharmaceuticals figures

See a number that looks wrong?